104 related articles for article (PubMed ID: 19620792)
1. [Status of components in EGFR-related signal transduction as predictive markers for anti-EGFR antibody therapy in colorectal cancer treatment].
Shimodaira H; Soeda H; Komine K; Ishioka C
Gan To Kagaku Ryoho; 2009 Jul; 36(7):1063-6. PubMed ID: 19620792
[TBL] [Abstract][Full Text] [Related]
2. Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR.
Heinemann V; Stintzing S; Kirchner T; Boeck S; Jung A
Cancer Treat Rev; 2009 May; 35(3):262-71. PubMed ID: 19117687
[TBL] [Abstract][Full Text] [Related]
3. [Predictive biomarkers for anti-EGFR antibodies].
Bando H; Yoshino T
Gan To Kagaku Ryoho; 2012 Nov; 39(11):1618-25. PubMed ID: 23152013
[TBL] [Abstract][Full Text] [Related]
4.
van Brummelen EMJ; de Boer A; Beijnen JH; Schellens JHM
Oncologist; 2017 Jul; 22(7):864-872. PubMed ID: 28576857
[TBL] [Abstract][Full Text] [Related]
5. Oncogenic mutations as predictive factors in colorectal cancer.
Lièvre A; Blons H; Laurent-Puig P
Oncogene; 2010 May; 29(21):3033-43. PubMed ID: 20383189
[TBL] [Abstract][Full Text] [Related]
6. Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?
Rizzo S; Bronte G; Fanale D; Corsini L; Silvestris N; Santini D; Gulotta G; Bazan V; Gebbia N; Fulfaro F; Russo A
Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S56-61. PubMed ID: 21129611
[TBL] [Abstract][Full Text] [Related]
7. [Predictive biomarkers of anti-EGFR monoclonal anti-body in colorectal cancer].
Soeda H; Shimodaira H; Ishioka C
Gan To Kagaku Ryoho; 2011 Jul; 38(7):1079-83. PubMed ID: 21772090
[TBL] [Abstract][Full Text] [Related]
8. PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies.
Sartore-Bianchi A; Martini M; Molinari F; Veronese S; Nichelatti M; Artale S; Di Nicolantonio F; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
Cancer Res; 2009 Mar; 69(5):1851-7. PubMed ID: 19223544
[TBL] [Abstract][Full Text] [Related]
9. Biomarkers for predicting the efficacy of anti-epidermal growth factor receptor antibody in the treatment of colorectal cancer.
Okada Y; Miyamoto H; Goji T; Takayama T
Digestion; 2014; 89(1):18-23. PubMed ID: 24458108
[TBL] [Abstract][Full Text] [Related]
10. Markers for EGFR pathway activation as predictor of outcome in metastatic colorectal cancer patients treated with or without cetuximab.
Tol J; Dijkstra JR; Klomp M; Teerenstra S; Dommerholt M; Vink-Börger ME; van Cleef PH; van Krieken JH; Punt CJ; Nagtegaal ID
Eur J Cancer; 2010 Jul; 46(11):1997-2009. PubMed ID: 20413299
[TBL] [Abstract][Full Text] [Related]
11. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
László L
Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
[TBL] [Abstract][Full Text] [Related]
12. Potential predictive markers of response to EGFR-targeted therapies in colorectal cancer.
Spano JP; Milano G; Vignot S; Khayat D
Crit Rev Oncol Hematol; 2008 Apr; 66(1):21-30. PubMed ID: 18206383
[TBL] [Abstract][Full Text] [Related]
13. Additional value of EGFR downstream signaling phosphoprotein expression to KRAS status for response to anti-EGFR antibodies in colorectal cancer.
Perkins G; Lièvre A; Ramacci C; Méatchi T; de Reynies A; Emile JF; Boige V; Tomasic G; Bachet JB; Bibeau F; Bouché O; Penault-Llorca F; Merlin JL; Laurent-Puig P
Int J Cancer; 2010 Sep; 127(6):1321-31. PubMed ID: 20049837
[TBL] [Abstract][Full Text] [Related]
14. Prognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy.
Lo Nigro C; Ricci V; Vivenza D; Granetto C; Fabozzi T; Miraglio E; Merlano MC
World J Gastroenterol; 2016 Aug; 22(30):6944-54. PubMed ID: 27570430
[TBL] [Abstract][Full Text] [Related]
15. New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?
Bronte G; Silvestris N; Castiglia M; Galvano A; Passiglia F; Sortino G; Cicero G; Rolfo C; Peeters M; Bazan V; Fanale D; Giordano A; Russo A
Oncotarget; 2015 Sep; 6(28):24780-96. PubMed ID: 26318427
[TBL] [Abstract][Full Text] [Related]
16. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study.
Moroni M; Veronese S; Benvenuti S; Marrapese G; Sartore-Bianchi A; Di Nicolantonio F; Gambacorta M; Siena S; Bardelli A
Lancet Oncol; 2005 May; 6(5):279-86. PubMed ID: 15863375
[TBL] [Abstract][Full Text] [Related]
17. Potential biomarkers for anti-EGFR therapy in metastatic colorectal cancer.
Yang J; Li S; Wang B; Wu Y; Chen Z; Lv M; Lin Y; Yang J
Tumour Biol; 2016 Sep; 37(9):11645-11655. PubMed ID: 27422777
[TBL] [Abstract][Full Text] [Related]
18. Combined assessment of epidermal [corrected] growth factor receptor dual color in situ hybridization and immunohistochemistry with downstream gene mutations in prediction of response to the anti-EGFR therapy for patients with metastatic colorectal cancer.
Takahashi N; Yamada Y; Taniguchi H; Honma Y; Iwasa S; Kato K; Hamaguchi T; Shimada Y
Arch Med Res; 2014 Jul; 45(5):366-74. PubMed ID: 24830936
[TBL] [Abstract][Full Text] [Related]
19. Analysis of KRAS, BRAF, PTEN, IGF1R, EGFR intron 1 CA status in both primary tumors and paired metastases in determining benefit from cetuximab therapy in colon cancer.
Park JH; Han SW; Oh DY; Im SA; Jeong SY; Park KJ; Kim TY; Bang YJ; Park JG
Cancer Chemother Pharmacol; 2011 Oct; 68(4):1045-55. PubMed ID: 21340604
[TBL] [Abstract][Full Text] [Related]
20. Analysis of PTEN, BRAF, and EGFR status in determining benefit from cetuximab therapy in wild-type KRAS metastatic colon cancer.
Laurent-Puig P; Cayre A; Manceau G; Buc E; Bachet JB; Lecomte T; Rougier P; Lievre A; Landi B; Boige V; Ducreux M; Ychou M; Bibeau F; Bouché O; Reid J; Stone S; Penault-Llorca F
J Clin Oncol; 2009 Dec; 27(35):5924-30. PubMed ID: 19884556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
